Evidence map›Paper›PMID 42394871›Full record

ArticleiGIE : innovation, investigation and insights2026

Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis.

Malek Shatila, Carolina Colli Cruz, Krishnavathana Varatharajalu, Andres Caleb Urias Rivera, Kian Abdul-Baki, Kei Takigawa, Tanvi Gupta, Elliot Baerman, Linfeng Lu, Irene Jeong-Ah Lee and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iGIE : innovation, investigation and insights, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Malek ShatilaThe University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology, and Nutrition, Houston, Texas, USA.
Carolina Colli CruzThe University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology, and Nutrition, Houston, Texas, USA.
Krishnavathana VaratharajaluThe University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology, and Nutrition, Houston, Texas, USA.
Andres Caleb Urias RiveraBaylor College of Medicine, Department of Internal Medicine, Houston, Texas, USA.
Kian Abdul-BakiThe University of Texas Medical Branch, Department of Internal Medicine, Galveston, Texas, USA.
Kei TakigawaBaylor College of Medicine, Department of Internal Medicine, Houston, Texas, USA.
Tanvi GuptaThe University of Texas Health Sciences Center, Department of Internal Medicine, Houston, Texas, USA.
Elliot BaermanBaylor College of Medicine, Department of Internal Medicine, Houston, Texas, USA.
Linfeng LuBaylor College of Medicine, Department of Internal Medicine, Houston, Texas, USA.
Irene Jeong-Ah LeeBaylor College of Medicine, Department of Internal Medicine, Houston, Texas, USA.
Hamza SalimThe University of Texas Medical Branch, Department of Internal Medicine, Galveston, Texas, USA.
Raakhi MenonThe University of Texas Medical Branch, Department of Internal Medicine, Galveston, Texas, USA.
Andrew SullivanThe University of Texas Health Sciences Center, Department of Internal Medicine, Houston, Texas, USA.
Varun VemulapalliThe University of Texas Health Sciences Center, Department of Internal Medicine, Houston, Texas, USA.
Cristina NathaThe University of Texas Health Sciences Center, Department of Internal Medicine, Houston, Texas, USA.
Ayesha KhanThe University of Texas Medical Branch, Department of Internal Medicine, Galveston, Texas, USA.
Petros GrivasUniversity of Washington Fred Hutchinson Cancer Center, Seattle, Washington, USA.
David FaleckMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Michael DouganDana Farber Cancer Institute, Boston, Massachusetts, USA.
Anusha Shirwaiker ThomasThe University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology, and Nutrition, Houston, Texas, USA.
Yinghong WangThe University of Texas MD Anderson Cancer Center, Department of Gastroenterology, Hepatology, and Nutrition, Houston, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Immune-mediated colitis (IMC) is a challenging adverse effect of immune checkpoint inhibitor therapy, often leading to treatment interruption or discontinuation. Current IMC endoscopic scoring systems were adapted from those used for inflammatory bowel disease but fail to fully capture IMC. The newly proposed IMC endoscopic score (IMCES) seeks to help guide prognosis and treatment. We aimed to validate IMCES and explore its association with IMC clinical severity and outcomes. Methods: This single-center retrospective study included patients with IMC who received immune checkpoint inhibitors and underwent endoscopic evaluation. IMCESs were calculated on the basis of 10 gross endoscopic features, as previously reported. Patients were divided into those with IMCES <4 and IMCES ≥4. Primary end points were selective immunosuppressive therapy (SIT) use, hospitalization, and clinical and endoscopic remission. Results: We evaluated 807 patients, including the 308 previously used to develop IMCES, with 499 in a validation cohort. We found that IMCES ≥4 was associated with need for steroids and SIT ( Conclusions: IMCES ≥4 had a high specificity for the need for SIT and was associated with worse outcomes. Given the importance of risk stratification in the treatment of IMC to inform the early introduction of SIT, IMCES may be a powerful clinical tool to estimate prognosis and guide management but requires further validation.

Identifiers

PMID42394871
PMCPMC13323902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.